Standard Biotools Inc Accounts Receivables Turnover Ratio from the third quarter 2025 to the third quarter 2024

Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)

Comprehensive Proteomics Profiling Unveils Novel Biomarkers and Insights into Nonalcoholic Steatohepatitis (NASH)Interest in nonalcoholic steatohepatitis (NASH) has burgeoned in recent years as researchers deepen their understanding of its pathophysiology and resultant clinical sequelae. NASH, a severe form of nonalcoholic fatty liver disease (NAFLD), is characterized by liver inflammation and damage due to fat accumulation, potentially progressing to cirrhosis or liver cancer. Despite advances in clinical research, the molecular underpinnings of NASH remain elusive, posing significant barriers to the development of effective diagnostics and therapeutics. Recent advancements in proteomics, particularly through efforts spearheaded by Standard BioTools, have illustrated a promising avenue for unveiling unique biomarkers and new insights into this complex disease. Proteomics: An Essential Tool for NASH ResearchProteomics, the large-scale study of proteins, offers a powerful lens through which to dissect the molecular mechanisms underlying diseases such as NASH. Unlike genomics, which focuses on the relatively static blueprint of DNA, proteomics examines the dynamic, functional entities that actually drive biological processes. Proteins constitute the biomolecular machinery of cells and tissues, making proteomics instrumental in understanding disease processes, identifying biomarkers, and elucidating therapeutic targets.